Literature DB >> 23233074

The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.

Yoshikazu Miyasaka1, Kenji Suzuki, Kazuya Takamochi, Takeshi Matsunaga, Shiaki Oh.   

Abstract

OBJECTIVES: Fluorodeoxyglucose positron emission tomography (FDG-PET) plays an important role in the evaluation of resectable non-small-cell lung cancer (NSCLC). However, this modality cannot be used to detect histological nodal involvement, which can result in stage-migration for resectable lung cancer. In this study, we tried to evaluate the possibility of predicting histological nodal involvement in patients with NSCLC using the maximum standardized uptake value (SUVmax) of FDG-PET of the primary tumour instead of that of the lymph nodes.
METHODS: Between February 2008 and September 2011, 898 patients underwent lung cancer surgery at our institute. Among them, we retrospectively analysed 265 patients with clinical N0 NSCLC, who underwent preoperative FDG-PET. The relationships between clinicopathological features, including the findings of FDG-PET and pathological nodal involvement, were investigated. The factors investigated were age, gender, preoperative carcinoembryonic antigen titre, maximum tumour dimension, consolidation/tumour dimension ratio (C/T ratio), SUVmax in the primary tumour and smoking history.
RESULTS: Of the 265 clinical N0 NSCLC patients, 214 (80.8%) had pathological N0 status and 27 (10.2%) and 24 (9.0%) had pathological N1 and N2 disease. In a multivariate analysis, the C/T ratio (P = 0.046) and SUVmax of the primary tumour (P = 0.016) were significant predictors of pathological nodal involvement. With regard to pathological N1-2 disease, the sensitivity, specificity, accuracy and positive and negative predictive values of mediastinal node involvement in patients with NSCLC with an SUVmax for FDG-PET of 10 or more were 49.0, 83.2, 76.6, 41.0 and 87.3%, respectively. Of the 61 patients with NSCLC with an SUVmax for FDG-PET of 10 or more, 25 (41.0%) had pathological N1-2 disease, while only 26 (12.7%) of the remaining 204 patients with an SUVmax for FDG-PET of <10 had nodal disease (P < 0.0001).
CONCLUSIONS: Postoperative nodal status was significantly predicted by the SUVmax of FDG-PET of the primary tumour instead of the lymph nodes themselves. The patients with NSCLC in particular who show strong uptake values of SUVmax in the primary tumour could have occult nodal metastases, and may be indicated for a further preoperative modality for an accurate staging.

Entities:  

Keywords:  Fluorodeoxyglucose positron emission tomography; Non-small-cell lung cancer; Pathological nodal involvement

Mesh:

Substances:

Year:  2012        PMID: 23233074     DOI: 10.1093/ejcts/ezs604

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  21 in total

1.  Prediction of pathological nodal involvement by CT-based Radiomic features of the primary tumor in patients with clinically node-negative peripheral lung adenocarcinomas.

Authors:  Ying Liu; Jongphil Kim; Yoganand Balagurunathan; Samuel Hawkins; Olya Stringfield; Matthew B Schabath; Qian Li; Fangyuan Qu; Shichang Liu; Alberto L Garcia; Zhaoxiang Ye; Robert J Gillies
Journal:  Med Phys       Date:  2018-04-29       Impact factor: 4.071

2.  Tumour standardized uptake value on positron emission tomography is a novel predictor of adenocarcinoma in situ for c-Stage IA lung cancer patients with a part-solid nodule on thin-section computed tomography scan.

Authors:  Aritoshi Hattori; Kenji Suzuki; Takeshi Matsunaga; Mariko Fukui; Yukio Tsushima; Kazuya Takamochi; Shiaki Oh
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-12-18

3.  Is single-station N2 disease on PET-CT an indication for primary surgery in lung cancer patients?

Authors:  Janusz Kowalewski; Tomasz J Szczęsny
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

4.  Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer.

Authors:  Yoichi Ohtaki; Kimihiro Shimizu; Kyoichi Kaira; Toshiteru Nagashima; Kai Obayashi; Seshiru Nakazawa; Seiichi Kakegawa; Hitoshi Igai; Mitsuhiro Kamiyoshihara; Masahiko Nishiyama; Izumi Takeyoshi
Journal:  Surg Today       Date:  2016-01-19       Impact factor: 2.549

5.  Predicted extracapsular invasion of hilar lymph node metastasis by fusion positron emission tomography/computed tomography in patients with lung cancer.

Authors:  Takashi Makino; Yoshinobu Hata; Hajime Otsuka; Satoshi Koezuka; Kazutoshi Isobe; Nobumi Tochigi; Nobuyuki Shiraga; Kazutoshi Shibuya; Sakae Homma; Akira Iyoda
Journal:  Mol Clin Oncol       Date:  2015-07-01

6.  Impact of maximum standardized uptake value of non-small cell lung cancer on detecting lymph node involvement in potential stereotactic body radiotherapy candidates.

Authors:  Shanyuan Zhang; Shaolei Li; Yuquan Pei; Miao Huang; Fangliang Lu; Qingfeng Zheng; Nan Li; Yue Yang
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

7.  Risk Factors for Occult Lymph Node Metastasis in Peripheral Non-Small Cell Lung Cancer with Invasive Component Size 3 cm or Less.

Authors:  Youngkyu Moon; Si Young Choi; Jae Kil Park; Kyo Young Lee
Journal:  World J Surg       Date:  2020-05       Impact factor: 3.352

8.  Prognosis of upstaged N1 and N2 disease after curative resection in patients with clinical N0 non-small cell lung cancer.

Authors:  Jae Kil Park; Youngkyu Moon
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

9.  Metabolic parameters using ¹⁸F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma.

Authors:  Do-Hoon Kim; Bong-Il Song; Chae Moon Hong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-03       Impact factor: 9.236

10.  Limitations of PET/CT in the Detection of Occult N1 Metastasis in Clinical Stage I(T1-2aN0) Non-Small Cell Lung Cancer for Staging Prior to Stereotactic Body Radiotherapy.

Authors:  Adil S Akthar; Mark K Ferguson; Matthew Koshy; Wickii T Vigneswaran; Renuka Malik
Journal:  Technol Cancer Res Treat       Date:  2016-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.